Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013 IV A. Verification: Difference between revisions

From GxPlex

Jump to: navigation, search
← Older edit
gxplex>GxPlexBot
Import from GxPlex Excel
m 1 revision imported
Β 
(11 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{#set:
{{ReferenceData
|HasDocument=Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013
|has_document=Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013
|RefScope=G
|module=3
|RefDocPart=IV A. Verification
|unit=3.1.1
|RefLanguage=EN
|scope=G
|RefTagsEN=
|doc_part=IV A. Verification
|RefTagsOriginal=
|language=EN
|RefTagsFR=
|entry_by=Florian Adragna
}}
|contributors=
Β 
|tags=TAG-00137-Mon-che ++ TAG-00140-Ris-nRi ++ TAG-00029-Inf-rte ++ TAG-00065-Sou-nΓΌb
== Document Information ==
|tags_display=[[Glossary:TAG-00137-Mon-che|Monitoring]], [[Glossary:TAG-00140-Ris-nRi|Risk-based monitoring]], [[Glossary:TAG-00029-Inf-rte|Informed consent]], [[Glossary:TAG-00065-Sou-nΓΌb|Source data verification]]
{{:Document:USA FDA Guidance for Industry - Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013}}
|comment=Risk-based monitoring: verification of informed consent
Β 
|content=IV. RISK-BASED MONITORING
== Reference Details ==
{| class="wikitable" style="width:100%;"
|-
! scope="row" style="width:200px;" | Scope
| G
|-
! scope="row" style="width:200px;" | Document part
| IV A. Verification
|-
! scope="row" style="width:200px;" | Language
| EN
|-
! scope="row" style="width:200px;" | Original entry by
| Florian Adragna
|-
! scope="row" style="width:200px;" | Contributors
|
|-
! scope="row" style="width:200px;" | Tags (EN)
|
|-
! scope="row" style="width:200px;" | Tags (original language)
|
|-
! scope="row" style="width:200px;" | Tags (FR)
| Β 
|-
! scope="row" | Comment
| Risk-based monitoring: verification of informed consent
|}
Β 
== Text ==
IV. RISK-BASED MONITORING
[…]
[…]
A. Identify Critical Data and Processes to be Monitored
A. Identify Critical Data and Processes to be Monitored
Line 50: Line 17:
β€’ Verification that informed consent was obtained appropriately
β€’ Verification that informed consent was obtained appropriately
[...]
[...]
}}

Latest revision as of 13:49, 16 July 2026



Document information
Reference USA FDA Guidance for Industry -

Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring Aug-2013

Validity area USA
Scope(s) G
Document name FDA Guidance for Industry -

Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring

Version / Revision Aug-2013
Status Current
Document type Official recommendation
Language(s) EN
Description Oversight of Clinical Investigations β€” A Risk-Based Approach to Monitoring

Guidance for Industry

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 3 β€” Unit 3.1.1
Scope G
Document part IV A. Verification
Language EN
Original entry by Florian Adragna
Contributors
Tags Monitoring, Risk-based monitoring, Informed consent, Source data verification

Content

IV. RISK-BASED MONITORING […] A. Identify Critical Data and Processes to be Monitored […] β€’ Verification that informed consent was obtained appropriately [...]

Retrieved from "https://gxplex.org/index.php?title=Reference:USA_FDA_Guidance_for_Industry_-_Oversight_of_Clinical_Investigations_β€”_A_Risk-Based_Approach_to_Monitoring_Aug-2013_IV_A._Verification&oldid=18201"